On November 3, 2026 Decoy Therapeutics, Inc. (NASDAQ: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs) to target major respiratory and high-consequence viral threats, reported a business update for the third quarter ended September 30, 2026. During the quarter, Decoy advanced its lead pan-coronavirus program toward the clinic and identified an optimized lead candidate with potential for once-weekly dosing.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Third Quarter 2026 Highlights

Lead program timing: Decoy expects to file a Clinical Trial Application (CTA) or Investigational New Drug (IND) application in 2H 2027 to begin a Phase 1 trial of its pan-coronavirus candidate.
Manufacturing planning: Decoy is evaluating manufacturing locations and is in discussions with manufacturers of pulmonary delivery systems to support clinical development of its pan-coronavirus candidate.
Once-weekly dosing potential: In preclinical studies, the optimized lead candidate showed potential for once-weekly dosing, compared to daily dosing for earlier candidates.
Pan-filovirus program: Decoy is exploring a program targeting Ebola, Marburg and related viruses.
Non-dilutive funding: The Company has met with U.S. government and military agencies and has applied, or is applying, for several non-dilutive funding opportunities and strategic collaborations.
Cash on hand: $8.1 million on the balance sheet at September 30, 2026.
"We are making excellent progress toward the clinic with our pan-coronavirus program, and our AI-enabled IMP³ACT platform continues to rapidly produce potential drug candidates against some of the world’s deadliest viruses," said Rick Pierce, Chief Executive Officer of Decoy Therapeutics. "We are focused on advancing these programs efficiently, including leveraging non-dilutive funding from top-tier collaborators."

Pan-Coronavirus Program

Decoy’s lead program is designed to protect people at high risk from respiratory coronaviruses, including patients with chronic obstructive pulmonary disease (COPD), immunocompromised patients and transplant recipients. There are no approved therapies for endemic human coronaviruses. The program is partially funded by the Gates Foundation, and the Company plans to follow Phase 1 with a Phase 2a human challenge trial at hVivo, a contract research organization (CRO) based in the United Kingdom.

Less frequent dosing could improve adherence in high-risk patients and lower the Company’s cost of goods. D-MAVs are designed for use both before exposure (pre-exposure prophylaxis) and after exposure (post-exposure prophylaxis).

Pipeline and Funding

Decoy’s pan-filovirus program targets Ebola, Marburg and related viruses, and the Company is pursuing non-dilutive funding to support preclinical and clinical work across its programs. Decoy is also seeking strategic collaborations for its existing programs and new drug discovery partnerships, and seclidemstat, an investigational LSD1 inhibitor from the Company’s legacy oncology portfolio, is available for license or sale.

Financial Update

Cash on balance sheet was $8.1 million at September 30, 2026, including approximately $2.5 million in restricted Gates Foundation grant funding.
As of September 30, 2026, Decoy had 2,385,282 shares of common stock outstanding.

(Press release, Decoy Therapeutics, NOV 3, 2026, View Source [SID1234674127])